Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 11, 2020 and accepted by EDGAR at Mar 11, 2020, 06:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$45.4m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$44.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$3.25 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$41.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $397.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $62.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $71.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $75.0m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $12.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $15.1m | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $168.0k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-12-31 | $208.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2019-12-31 | $58.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001544227-20-000004. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.